Correlation between Serum Parathyroid Hormone and Markers of Bone Metabolism in Hemodialysis Patients

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

3 Msc Student, Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Renal osteodystrophy is a common finding in patients with chronic kidney disease (CKD) requiring dialysis (stages 3-5). Increased serum activity of bone isoform alkaline phosphatase is a good marker for investigating uremic osteodystrophy in these patients. Considering the important effect of vitamin D on calcium, mineral homeostasis and parathyroid hormone (PTH), the objective of this study was investigation of association between serum levels of PTH, 25(OH)D3, Alkaline phosphatase (ALP), calcium (Ca) and inorganic phosphate (Pi) in hemodialysis patients.Methods: Ninety hemodialysis patients were included in this study. Mean age of the patients was 36.0 ± 11.4 years and duration of receiving dialysis was 2 months to 23 years (Mean ± SD: 80 ± 71 months). The serum levels of 25(OH)D3, ALP, Ca and Pi and PTH were measured. Data analysis was performed using SPSS software.Findings: Abnormal levels of serum Ca and Pi were more common in men than women (Ca: 63.6% versus 52.8%, Pi: 72.7% versus 50%, in men and women respectively); but more women had abnormal serum levels of ALP, PTH and vitamin D compared to men (ALP: 75% versus 54.5%, PTH: 97.2% versus 94.5%, 25(OH) D3: 63.9% versus 32.7%, in women and men respectively). Statistical correlation between serum levels of ALP and PTH (P = 0.0500), PTH and hemodialysis duration (r = 0.588, P < 0.0005) were significant. No statistically significant correlation was observed between serum levels of PTH and other biochemical factors.Conclusion: In the majority of studied patients, the serum Pi and PTH levels were out of normal ranges that indicate poor management of hyperparathyroidism and Pi in these patients. According the results of this study, the intensity of secondary hyperparathyroidism and its deleterious effects on bone tissue was more common in women than men.

Keywords

References

  1. Wolisi GO, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 2005; 18(4): 307-14.
  2. Skorecki K, Green J, Brenner BM. Chronic renal failure. In: Fauci AS, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL. Harrison's principles of internal medicine. 16th. New York, NY: McGraw-Hill; p. 1653.
  3. Moe S, Drueke T, Block G, Cannata-Andia J, Elder G, Fukagawa M, etal. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; (113): S1-130.
  4. Martin KJ, Gonzalez EA. Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol 2004; 24(5): 456-9.
  5. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147(12): 5542-8.
  6. Plum L, DeLuca H. The functional metabolism and molecular biology of vitamin D action. Clinic Rev Bone Miner Metab 2009; 7(1): 20-41.
  7. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009; 94(1): 26-34.
  8. Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 2007; 103(3-5): 316-21.
  9. Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1992; 89(17): 8097-101.
  10. Wong RG, Norman AW, Reddy CR, Coburn JW. Biologic effects of 1,25-dihydroxycholecalciferol (a highly active vitamin D metabolite) in acutely uremic rats. J Clin Invest 1972; 51(5): 1287-91.
  11. Lorenzo S, V, Torregrosa V. Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis). Nefrologia 2008; 28(Suppl 3): 67-78. [In Spanish].
  12. Amin H, Wall BM, Cooke CR. Osteomalacia and secondary hyperparathyroidism after kidney transplantation: Relationship to vitamin D deficiency. Am J Med Sci 2007; 333(1): 58-62.
  13. Tanaka H, Komaba H, Fukagawa M. Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism. Clin Calcium 2011; 21(11): 27-34. [In Japanese].
  14. Sanchez Navarro MR, Fernandez-Conde ME, Blanco MS, Samaniego C. Alkaline phosphatase isoenzymes in the serum of patients with renal insufficiency. An Med Interna 2002; 19(9): 449-52. [In Spanish].
  15. Oste L, Bervoets AR, Behets GJ, Dams G, Marijnissen RL, Geryl H, et al. Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats. Kidney Int 2005; 67(3): 920-30.
  16. Ho LT, Sprague SM. Renal osteodystrophy in chronic renal failure. Semin Nephrol 2002; 22(6): 488-93.
  17. Drueke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48(1): 259-72.
  18. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 2000; 54(4): 318-24.
  19. Rodriguez M, Martin-Malo A, Martinez ME, Torres A, Felsenfeld AJ, Llach F. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol. Kidney Int 1991; 40(6): 1055-62.
  20. Tabata T, Shoji S, Morita A, Emoto M, Inoue T, Miki T, et al. Effects of dietary phosphorus restriction on secondary hyperparathyroidism in hemodialysis patients during intermittent oral high-dose 1,25(OH)2D3 treatment. J Nutr Sci Vitaminol (Tokyo) 1991; 37(Suppl): S105-S112.
  21. Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MW, Larsson L. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 2001; 60(1): 257-65.
  22. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63(4): 284-9.
  23. Rubini G, Anelli F, Correale M, Lauriero F, Rubini D, D'Addabbo A. Renal osteodystrophy with hyperparathyroidism: the diagnostic value of intact parathormone, alkaline phosphatase, osteocalcin and procollagen. J Nucl Biol Med 1994; 38(3): 489-94.
  24. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993; 44(5): 1071-7.
  25. Rahimian M, Behzad F, Sami R. Prevalence of secondary hyper parathyroidism in hemodialysis patients. J Shaheed Sadoughi Univ Med Sci 2007; 15(1): 3-8. [In Persian].
  26. Brenner B. Brenner and Rector's the kidney. 6th ed. Philadelphia, PA: Saunders; 2000. p. 2103-6, 2121, 2137, 2416.
  27. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's principles of internal medicine. 15th ed. New York, NY: McGraw-Hill; 2001.
  28. Shariati AR, Mojerloo M, Hesam M, Nasiri H, Roohi Gh. Relationship between serum parathyroid hormone level and some factors in hemodialysis patients. Journal of Gorgan Bouyeh Faculty of Nursing and Midwifery 2007; 4(2): 27-33. [In Persian].
Journal of Isfahan Medical School
Volume 31, Issue 244 - Serial Number 244
May and June 2013
Pages 1059-1066

Files

History

  • Receive Date: 11 June 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics